We are live on
!
Find out more
Catalyst Pharmaceutical
CPRX
CPRX
360 hedge funds and large institutions have $2.04B invested in Catalyst Pharmaceutical in 2025 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 129 increasing their positions, 134 reducing their positions, and 49 closing their positions.
New
Increased
Maintained
Reduced
Closed
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
1.33% more ownership
Funds ownership: 83.09% → 84.42% (+1.3%)
0% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 49
4% less repeat investments, than reductions
Existing positions increased: 129 | Existing positions reduced: 134
1% less funds holding
Funds holding: 365 → 360 (-5)
7% less capital invested
Capital invested by funds: $2.2B → $2.04B (-$164M)
55% less call options, than puts
Call options by funds: $4M | Put options by funds: $8.84M
Holders
360
Holders Change
-5
Holders Change %
-1.37%
% of All Funds
4.73%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
49
Increased
129
Reduced
134
Closed
49
Calls
$4M
Puts
$8.84M
Net Calls
-$4.83M
Net Calls Change
+$967K
Top Buyers
| 1 |
DM
Deerfield Management
New York
|
+$43.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$19.1M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$15.8M |
| 4 |
Millennium Management
New York
|
+$15.4M |
| 5 |
Fundsmith LLP
London,
United Kingdom
|
+$13.5M |
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$28.9M |
| 2 |
Morgan Stanley
New York
|
-$27.6M |
| 3 |
BlackRock
New York
|
-$14.1M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$9.13M |
| 5 |
O
OrbiMed
New York
|
-$9.05M |
